News on technologies and applications for point-of-care testing.
The Seattle-based firm believes its novel collection devices are convenient and safe enough to use at home to draw blood for many types of tests.
The test will use a Gauss-developed mobile phone app that provides instructions on sample collection and provides results within 15 minutes.
Capitainer said that the deal with Speciality Diagnostix will help it meet strong interest for dried-blood-spot sampling in current and new applications.
The test is designed to detect and differentiate SARS-CoV-2, influenza A, and influenza B and runs on the company's benchtop Cobas Liat system.
The company and its collaborators previously published a study linking saliva concentrations of multiple microRNAs with concussion duration and symptoms in children.
